Google Wants to Slow Down Aging, But at What Price?

Ben Benoy Economy and MarketsThis year Alphabet (NASDAQ: GOOG), formerly known as Google, has been in a full court press to leverage their massively advanced computing infrastructure to figure out a way to do the unthinkable: slow down human aging!

The irony of this whole effort is that Calico, a biotech spinoff company of Alphabet, is running out of data to crunch. They’re simply having a hard time finding people willing to donate their DNA.

Google Ventures CEO Bill Maris, the man behind Calico, essentially told an interviewer earlier in the week that people should stop whining and give their DNA to Google to play with.

Maris has also suggested that people’s DNA isn’t really private: we shed massive amounts of skin cells every day in public. Researchers could just dig in your trash and find a fresh sample.

Disregarding the fact that simply isn’t true – researchers currently need a much bigger sample than just a couple cells to get any real genetic insight – his suggestions have caused a bit of an uproar.

He’s offered some pretty stark words for his naysayers, however: “If we keep our genetic information secret, then we’re all going to die.” Last time I checked, there were only two certainties in life: death, and taxes. But I digress.

There’s also the accountability issue. Earlier in the year, biotech company 23andMe – which Maris’ firm invests in – got in a lot of hot water for selling $100 DNA kits to people who wanted to know their ancestry… then re-selling the private data its customers paid for to large pharmaceutical companies for heaps of cash.

Or how about the case of the late Henrietta Lacks, whose cells were experimented on for 25 years without her family knowing… but led to breakthroughs in the polio vaccine, cloning, gene mapping, and in vitro fertilization.

Clearly some good comes from this. But where do we draw the line?

No matter what side of the argument you’re on, one thing is certain – Alphabet and other Big Tech firms are out to get your personal DNA, because human genome analytics is turning into a massive business.

Personally, I think if proper controls are in place, our DNA data could be used for more good than evil, but only time will tell. I am closely tracking the DNA analytics trend via my social media collective intelligence system and am planning on making some market plays in my BioTech Intel Trader service.

Ben Benoy

Ben Benoy
Editor, Biotech Intel Trader

What You Need to Know About the Safe-Asset Slaughter!

You’re not going to believe what’s on the horizon…

The final bubble of the recent financial crisis is about to burst. When it pops – it could be as soon as November 2014 – millions of Americans will be financially devastated… But others will have the opportunity to get much richer.

This controversial video reveals how you can end up on the winning side of the coming carnage…

Click to Learn More
Categories: Biotech

About Author

Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.